Tag Archives: Ariad pharmaceuticals

January, 2017

• 9 January

  Takeda to Acquire ARIAD Pharmaceuticals for $5.2 Billion

  

  CAMBRIDGE, Mass. & OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:4502) (“Takeda”) and ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) (“ARIAD”) today announced that they have entered into a definitive agreement under which Takeda will acquire all of the outstanding shares in ARIAD for $24.00 per share in cash, or an enterprise value of …

  Share

  • Facebook
  • Twitter
  • LinkedIn

April, 2016

• 15 April

  Ariad Presents Updated Phase 1/2 Data on its NSCLC Drug

  

  GENEVA & CAMBRIDGE, Mass.–(BUSINESS WIRE)–ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced updated clinical data on its investigational tyrosine kinase inhibitor, brigatinib, in patients with advanced malignancies, including anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC), from an ongoing Phase 1/2 trial. This report includes updated data on the …

  Share

  • Facebook
  • Twitter
  • LinkedIn